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Abstract There is ongoing controversy as to whether
hormonal changes of the euthyroid sick syndrome are
predictors of poor outcome in sepsis and critical illness. In
this prospective study, the prognostic accuracy of thyroid
hormone levels in 103 critically ill adult patients on admis-
sion and during follow up in a medical intensive care unit
(ICU) was assessed and was compared to clinical risk scores,
namely, the acute physiology and chronic health evaluation
and the simplified acute physiology score. Median T3 levels
on admission to the ICU were lower in the 53 septic cases
[0.9 nmol/l (IQR 0.6–1.1)] as compared with the 50 patients
with a systemic inflammatory response syndrome [1.2 nmol/
l (IQR 0.8–1.4), P \ 0.001]. The lowest T3 levels were
found in patients with severe sepsis [0.8 nmol/l (IQR
0.55–0.95)] and septic shock [0.8 nmol/l (IQR 0.6–1.0)].
There was no difference in T3 and free thyroxin (fT4) levels
on admission in non-survivors compared with survivors
overall and in subgroups of patients with SIRS and sepsis.
During the follow up, fT4 levels decreased significantly in
non-survivors, while they increased in survivors [fT4
difference -1.3 (IQR -2.5 to 0.2) vs. 0.8 (IQR -0.85 to 4.1),
P = 0.003]. In addition, on the day of death, non-survivors
had lower T3 and fT4 levels as compared with survivors
(P = 0.04 and P = 0.02). T3 and fT4 levels on admission
were not prognostic in this cohort of critically ill patients. A
decrease in fT4 levels in the course of disease, however, may
point to adverse outcome.
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Introduction
Sepsis affects 750,000 people annually and accounts for
210,000 deaths every year in the USA despite improved
medical treatment strategies [1, 2]. To tackle the challenges
of early diagnosis and risk stratification, several clinical
prognostic scores have been developed. For this purpose,
the updated Acute Physiology and Chronic Health Evalu-
ation II (APACHE) and the Simplified Acute Physiology
Score II (SAPS) are extensively validated prognostic
assessment tools used in critically ill patients for stratifi-
cation of disease severity and estimation of in-hospital
mortality based on routine physiologic measurements, age,
and clinical parameters [3, 4]. Because the prognostic
accuracy of these clinical scores still demonstrates a level
of uncertainty, there is interest for novel prognostic bio-
markers, each mirroring different pathophysiological
mechanisms. In this context, endocrine markers such as
plasma concentrations of cortisol, adrenomedullin, and
growth hormone have been reported to correlate with
severity and outcome of septic adults and children [5–8].
Severity-dependent alterations in the thyroid axis during
critical illness are well known. The constellation of low
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total triiodothyronine (T3) levels, increased reverse T3
levels, and/or low total thyroxin (T4) levels with normal
free thyroxin (fT4) levels in the absence of an obvious
thyroid disease is commonly called the ‘‘euthyroid sick
syndrome’’ [9–11]. Some studies from different clinical
settings suggested that low levels of thyroid hormones are
predictors of poor outcome in sepsis and critical illness
[12–15]. However, other studies found no, or even oppo-
site, associations of thyroid hormone concentrations with
outcome [16, 17]. Thus, there still remains a controversy as
to whether changes in thyroid hormone levels add prog-
nostic information to the widely used clinical risk scores.
We therefore assessed the prognostic accuracy of thyroid
hormone levels in a cohort of critically ill adult patients on
admission and during follow up in a medical intensive care
unit (ICU).
Materials and methods
In this prospective study, thyroid hormone values in plasma
samples of 103 critically ill patients in the medical ICU of
the University Hospital of Basel, Switzerland were evalu-
ated. The primary objective of this study was to evaluate
the prognostic value of endocrine dysfunction in critical
illness (PEDCRIP study) [18]. More specifically, the study
aimed to evaluate the prognostic accuracy of thyroid- and
other hypothalamus-pituitary-axis hormones to predict
death in the ICU setting [18, 19]. A total of 103 critically ill
patients were enrolled over a 9-month period. Assessment
of patients on admission was performed three times, i.e.,
during the first 24 h, on day 2, and at discharge from the
ICU or death. Clinical status, vital signs, and severity of
disease were monitored daily including the calculation of
the APACHE II and SAPS II. Depending on the clinical
status, informed consent was obtained from the patient or
its relatives. Prior approval of the study protocol was
obtained from the ethical committee.
Patients were classified into systemic inflammatory
response syndrome (SIRS) without underlying infection
and sepsis including severe sepsis and septic shock based
on international consensus criteria [20, 21]. Classification
of patients was done after discharge of patients on the basis
of patient-chart review, results of microbiological cultures,
radiographs, and if available by post-mortem examination
reports. In case of uncertainty, an infectious disease spe-
cialist was asked for additional review of the case. An
isolated microorganism was considered to be pathogenic if
detected within 24 h before or after the onset of systemic
response. Colonization with bacteria (e.g., bacteruria in an
asymptomatic patient with a urine catheter) or post-mortem
positive blood cultures were disregarded.
Assay
Blood samples were obtained from an indwelling venous
or arterial catheter. Routine blood count, C-reactive pro-
tein (CRP), procalcitonin, and interleukin 6 (IL6) levels
were measured in all the patients. CRP (mg/l) was mea-
sured by an enzyme immunoassay (EMIT C-reactive
protein assay; E. Merck Diagnostica Zurich, Switzerland).
Procalcitonin (PCT) (ng/ml) was measured using the
immunoluminometric assay (LUMItest PCT; Brahms
Diagnostica Berlin, Germany) with a lower detection limit
of 0.1 lg/l. Serum IL6 concentrations (ng/ml) were
measured with a commercially available quantitative
sandwich enzyme immunoassay (CLB; Pelikine Com-
pactTM, Amsterdam, Netherlands) with a detection limit
of 0.6 pg/ml.
Plasma was collected at the time of blood sampling on
admission, day 2 and at discharge from the ICU or death,
respectively, in plastic tubes containing ethylenendiami-
netatraacetic (EDTA). The tubes were placed on ice, cen-
trifuged at 3,000 g, and plasma was stored at -70C until
assayed. T3 (nmol/l) and fT4 (pmol/l) concentrations were
measured by an electro-chemistry-luminescence immuno-
assay (ECLIA, Roche Diagnostics, Mannheim, Germany)
with a functional detection range of 0.3–10 nmol/l and
0.3–100 pmol/l, respectively.
We preferred measurement of total T3 over free T3
because in our experience and also according to the liter-
ature, free T3 measurement shows greater variability, and
thus the precision is less reliable for use in clinical practice
[22].
Statistical analysis
All data are presented as medians and interquartile ranges.
Levels that were not detectable were considered to have a
value equal to the lower limit of detection of the assay.
Frequency comparison was done by chi-square test. For not
normally distributed two-group comparison, the Mann–
Whitney-U test was used, and the Kruskal–Wallis one-way
analysis of variance was used if more than two groups were
being compared. Correlation analyses were performed
using Spearman rank correlation. These tests were done
using Graph Pad Prism (version 4, GraphPAd, la Jolla,
CA, USA) and STATISTICA (version 6, StatSoft, Tulsa,
OK, USA). Receiver-operating-characteristics (ROCs) were
calculated using MedCalc for windows (version 7.2.1.0.,
Mariakerke, Belgium).
All the statistic tests were two-tailed, and P values
less than 0.05 were considered to indicate statistical
significance.
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Results
Descriptive characteristics of patients
The median age of the 103 patients included in this study was
59 years (IQR 46–68.5) with 54.4% males. On admission,
the median APACHE II was 21 points (IQR 17–27.5) and the
median SAPS II was 54 points (IQR 43.5–66). The median
length of stay in the medical ICU was 3 days (IQR 1–4). On
admission, SIRS without underlying infection was diag-
nosed in 50 patients and sepsis in 53 patients including 15
patients with severe sepsis and 16 patients with septic shock.
Patient’s underlying diagnoses are summarized in Table 1.
The principal site of infection was the lung (n = 37), the
gastrointestinal tract (n = 5), the urogenital tract (n = 4),
and blood stream infection (n = 2). Blood cultures showed
growth of typical microorganisms in 31 patients including
Streptococcus pneumoniae (n = 9), Pseudomonas
aeruginosa (n = 6), E. coli (n = 6), Enterobacteriaceae
(n = 2), Haemophilus influenzae (n = 2), and Staphylo-
coccus aureus (n = 1). 30% of patients with SIRS were
treated with dopamine for blood pressure support compared
to 49.1% of patients with sepsis. IL6 levels were signifi-
cantly higher in patients with sepsis compared to patients
with SIRS (P \ 0.0001). Mortality rates of patients with
and without infection were similar: 22% of patients with
SIRS and 24.5% of patients with sepsis died in the hospital.
Baseline data of the whole patient cohort and those
grouped into survivors and non-survivors are summarized
in Table 2. No statistically significant difference was
detected between survivors and non-survivors concerning
age, sex, and common clinical parameters.
Prognostic assessment on admission showed a significantly
higher APACHE II and SAPS II in non-survivors as com-
pared with survivors [27 (IQR 19–31.8) vs. 21 (IQR 16–25.5)
and 67 (IQR 53.8–83) vs. 50 (IQR 39–62)]. Similarly, IL6 was
higher in non-survivors compared with survivors [260 ng/ml
(IQR 64.9–1167.5) vs. 48.9 ng/ml (IQR 9.3–177.5)].
Thyroid hormones on admission and during follow-up
The median T3 level of the 103 patients on admission was
1.0 nmol/l (IQR 0.7–1.2). In 66 patients (65%), a T3 level
below the lower reference range of 1.2 nmol/l was found,
while the other 36 patients (35%) had a T3 within the
normal range. The median fT4 level was 14.2 pmol/l (IQR
11.6–16.6). Twenty-five patients (24%) had fT4 levels
below, 71 patients (69%) within and 6 patients (6%) above
the normal reference range of 11.6–22.0 pmol/l.
On day 2, 58% of patients had T3 levels and 23% of patients
had fT4 levels below the reference range. On the day of
discharge or death, respectively, T3 levels and fT4 levels
below the reference range were found in 57% and 26% of
patients.
T3 levels on admission correlated with serum PCT
levels (r = 0.44, P \ 0.001) but not with the APACHE II
(r = -0.14, P = 0.14) or SAPS II (r = 0.15, P = 0.13).
FT4 levels did not correlate with PCT levels (r = 0.14,
P = 0.16), the APACHE II (r = -0.12, P = 0.22), or the
SAPS II (r = 0.17, P = 0.07).
T3 and fT4 levels in patients with SIRS, sepsis, severe
sepsis, and septic shock
Median T3 levels on admission to the ICU were lower in
septic patients [0.9 nmol/l (IQR 0.6–1.1)] as compared to
Table 1 Clinical diagnoses of patients
Clinical diagnoses of patients Number of
patients
Respiratory
Pneumonia 33
Chronic obstructive pulmonary disease 14
Asthma 3
Pharyngeal obstruction 2
Toxic pulmonary edema 2
Bronchiale carcinoma 3
Intestinal
Abdominal infection 6
Urinary tract infection 5
Gastrointestinal bleeding 7
Intestinal ischemia 1
Renal failure 1
Hepatic coma 3
Cardiovascular
Myocardial infarction 12
Heart failure 11
Pulmonary embolism 4
Hemorrhagic shock 1
Cerebral
Intracranial hemorrhage 3
Ischemic stroke 5
Subarachnoidal hemorrhage 4
Meningitis 1
Epilepsy 3
Sinus venous thrombosis 1
Other diagnosis
Intoxication 4
Diabetic coma 3
Postoperative 4
Others 2
Leukemia 7
One patient can have more than one diagnosis, therefore the total
exceeds the absolute number of patients
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patients with SIRS and no infection [1.2 nmol/l (IQR
0.8–1.4), P \ 0.001] (Fig. 1). In septic patients, the lowest
T3 levels were found in subgroups of patients with severe
sepsis [0.8 nmol/l (IQR 0.6–1.0)] and septic shock
[0.8 nmol/l (IQR 0.6–1.0)] (Fig. 2). There was no differ-
ence between the fT4 levels in patients with SIRS and in
patients with sepsis, as well as in subgroups of patients
with severe sepsis and septic shock.
T3 and fT4 levels and outcome of patients
T3 and fT4 levels on admission were not different between
non-survivors and survivors (P = 0.32 and P = 0.67)
(Fig. 3). The median T3 level in non-survivors was
0.9 nmol/l (IQR 0.7–1.1) compared to 1.0 nmol/l (IQR
0.7–1.3) in survivors. The median fT4 level was 13.6 pmol/l
(IQR 11.0–17.3) in non-survivors and 14.6 pmol/l (IQR
11.7–16.5) in survivors, respectively. Similarly, T3 and fT4
levels were not different between non-survivors and survi-
vors in subgroups of SIRS and septic patients, respectively.
Overall, there was no statistical difference between T3
(P = 0.08 and P = 0.46) and fT4 (P = 0.5 and 0.05)
levels on admission as compared to values obtained after
Table 2 Baseline data
Charcteristics All patients (n = 103) Survivors (n = 79) Non-survivors (n = 24) P
Demographic characteristics
Age-years-(median-IQR) 59 (46–68) 56 (46–67) 63 (52.5–73.3) 0.1
Female sex (%) 46 (n = 47) 47 (n = 37) 42 (n = 10) 0.4
Weight (kg)-median-IQR) 70.1 (62.5–81.3) 70.1 (61–84) 71 (65–79.3) 0.8
BMI (kg/m2)-(median-IQR) 24.2 (22.1–27.3) 24.2 (22.2–27.3) 24.2 (22.1–25.5) 0.8
Clinical findings
Heart rate (bpm)-(median-IQR) 107 (82–125) 110 (82.5–124) 97.5 (79–126) 0.9
Respirator-rate-(median-IQR) 16 (12–25) 16 (12–25) 14 (10.8–13.3) 0.3
Temperature (C)-(median-IQR) 36.7 (35.8–37.6) 36.8 (36–37.7) 36.5 (35.5–37.4) 0.3
Routine laboratory findings-(median-IQR)
C-reactive protein (mg/l) 81 (17–200) 74 (15.5–189) 84 (42.8–246.8) 0.5
Procalcitonin (lg/l) 1.1 (0.3–4.8) 1.1 (0.3–4.3) 2.4 (0.6–11.1) 0.2
IL6 (pg/ml) 69.4 (12.6–278) 48.9 (9.3–177.5) 260 (64.9–1167.5) 0.002
White blood count (9109) 11.1 (8.2–15.2) 10.3 (8.2–13.5) 13.6 (8.6–18.2) 0.09
Thyroid hormones (median-IQR)
T3 (nmol/l) on admission 1.0 (0.7–1.2) 1.0 (0.7–1.3) 0.9 (0.7–1.1) 0.3
fT4 (pmol/l) on admission 14.2 (11.6–16.6) 14.6 (11.7–16.5) 13.6 (11–17.3) 0.66
T3 (nmol/l) on day 2 1.0 (0.8–1.3) 1.1 (0.8–1.3) 0.9 (0.8–1.1) 0.08
fT4 (pmol/l) on day 2 14.6 (11.0–17.1) 14.7 (11.6–17.1) 11.8 (9.8–17) 0.2
T3 (nmol/l) at death or discharge 0.9 (0.7–1.3) 1.0 (0.7–1.3) 0.8 (0.7–0.9) 0.04
fT4 (pmol/l) at death or discharge 14.8 (11.2–17.7) 15.3 (12.3–18.3) 11.9 (6.9–15.8) 0.02
Prognostic scores on admission
APACHE II (points)-(median-IQR) 21 (17–28) 21 (16–25.5) 27 (19–31.8) 0.005
SAPS II (points)-(median-IQR) 54 (12.5–284) 50 (39–62) 67 (53–83) 0.0003
Co medication
Dopamin treatment (%) 39.8 (n = 41) 36.7 (n = 29) 50 (n = 12) 0.32
BMI body mass index, T3 triiodothyronine, fT4 free thyroxin, IL6 interleukin 6, APACHE II acute physiology and chronic health evaluation,
SAPS II simplified acute physiology score
Fig. 1 Admission T3 levels in patients with SIRS and sepsis
(including severe sepsis and septic shock). Lines denote median
values, each point represents one measurement. T3 triiodothyronine,
SIRS systemic inflammatory response syndrome
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2 days and at discharge from the ICU. However, during
follow up, fT4 levels significantly decreased in non-
survivors, while an increase in survivors was found [fT4
difference -1.3 (IQR -2.5 to 0.2) vs. 0.8 (IQR -0.85 to
4.1), P = 0.003]. On the day of death, non-survivors had
lower T3 and fT4 levels as compared with survivors
[0.8 nmol/l (IQR 0.7–0.9) vs.1.0 nmol/l (IQR 0.7–1.3),
P = 0.04 and 11.9 pmol/l (IQR 6.9–15.7) vs.15.3 pmol/l
(IQR 12.3–18.3), P = 0.02] (Fig. 4).
To investigate the prognostic potential of T3 and fT4
levels so as to predict mortality in patients with SIRS,
sepsis, severe sepsis, and septic shock, we performed
receiver operating characteristic (ROC) analysis. On com-
parison, the same ROC analysis values were obtained for
CRP, PCT, the SAPS II, and APACHE II. The area under
the curve (AUC) for T3 and fT4 on admission were 0.57
(IQR 0.47–0.67) and 0.53 (IQR 0.43–0.63), which was
lower as compared to the AUC’s of the SAPS II [AUC 0.76
(IQR 0.66–0.83)] and APACHE II [AUC 0.70 (IQR
0.60–0.79)]. On day 2 the AUCs of T3 and fT4 were 0.63
(IQR 0.52–0.73) and 0.59 (IQR 0.49–0.7) and at discharge
or death, respectively the AUCs were 0.65 (IQR 0.55–0.75)
and 0.68 (IQR 0.57–0.77).
Discussion
This study has demonstrated two major findings. First,
plasma T3 levels were lower in patients with sepsis as
compared to patients with SIRS despite similar mortality
rates. Second, circulating thyroid hormone levels measured
on admission were not different in survivors andFig. 2 Admission levels of T3 in patients with SIRS, sepsis, severe
sepsis and septic shock. Lines denote median values, each point
represents one measurement. T3 triiodothyronine, SIRS systemic
inflammatory response syndrome
Fig. 3 T3 levels on admission in survivors and non-survivors Lines
denote median values, each point represents one measurement. T3
triiodothyronine
Fig. 4 T3 and fT4 levels during admission and follow-up in survivors
and non-survivors. FT4 levels significantly decreased in non-survi-
vors, while an increase in survivors was found (P = 0.003). On the
day of death, non-survivors had lower T3 and fT4 levels as compared
with survivors (P = 0.04 and P = 0.02). Squares denote median
values, whiskers indicate range. T3 triiodothyronine, fT4 free thyroxin
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non-survivors and thus, did not give helpful prognostic
information.
The hypothesis that hormonal changes of the euthyroid
sick syndrome predict outcome in critically ill patients
remains unresolved [12, 13, 15, 16, 23–25]. Some studies
showed a correlation of low T3 levels and low T4 levels
with outcome in critically ill adults and children [13, 15,
23, 25]. However, concurrent with our findings, a few
studies did not detect any prognostic value of T3 and fT4
levels on admission to predict outcome [16, 17], and a few
other found even relatively higher total T3 levels in non-
surviving compared with surviving children with menin-
gococcal sepsis [12, 24].
Different theories have been propagated to explain the
mechanism and significance of the euthyroid sick syn-
drome. Acute and sustained critical illness results in
complex alterations in the thyroid axis in a bimodal pattern
[10, 11]. The acute initial phase is primarily characterized
by changes in the peripheral metabolism and receptor
binding of thyroid hormones, whereas in the chronic phase
a diminished hypothalamic-pituitary-activity with a timely
overlap of the two conditions is found [10, 11, 26]. The
chronic phase of the euthyroid sick syndrome is charac-
terized by reversibly diminished secretion of TSH which
can be reactivated by thyrotropin-releasing hormone
(TRH) administration [10, 11, 27].
The decrease in serum T3 and fT4 levels is a dynamic
process, which develops over time [14, 28]. Hence, the
typical adaptations of the thyroid axis may not be present in
critically ill patients on admission to the ICU which is
delayed with respect to the initiation of the critical illness
per se. This might explain the lack of association between
admission T3 and fT4 levels and outcome in our study
[12, 23, 24].
Accordingly, we found lower T3 and fT4 levels in non-
survivors compared to survivors only during follow-up
measurements. In agreement with this finding, Peeters et al.
found T3 and T4 levels on day 5 to be significantly lower in
critically ill patients who ultimately died compared to those
who survived [14]. Similar to our study, those authors
described an increase in peripheral thyroid hormones in
surviving patients whereas thyroid hormones in patients
who died decreased [14]. This is in line with previous
studies suggesting that an increase in TSH drives the rise in
T4 and thus points to the onset of recovery [29, 30]. There
is evidence that a marked decrease in T4 levels is associ-
ated with a high probability of death [10, 31].
In addition, cytokines have a direct action on thyroid
hormone synthesis through an effect on the hypothala-
mus and pituitary gland. It has been shown that short-
term infusion of IL6 to human volunteers causes a
suppression of TSH but daily injections over 42 days
caused only a modest decrease in T3 [32]. Antibody
blockade of IL6, on the other hand, failed to induce the
changes of the euthyroid sick syndrome in animal
models [33]. Thus, IL6 could be involved in the euthy-
roid sick syndrome, but the potential interactions
between cytokines and the hypothalamic pituitary thyroid
axis complicate the pathophysiological understanding as
cytokines themselves act in a network. However, the
higher IL6 levels in patients with sepsis as compared
with patients with SIRS in our study could explain the
finding that septic patients had lower T3 levels compared
to SIRS patients.
Furthermore, medication can alter thyroid hormones.
Hence, dopamine given to many patients in an ICU plays a
role in the development of euthyroid sick syndrome.
Dopamine treatment depresses the thyroid axis per se and
can aggravate the euthyroid sick syndrome by suppression
of the TSH secretion as well as the TSH response to TRH
[34–36]. 50% of the patients who died during our study
were treated with dopamine compared to only 36.7% of
patients who were discharged. This could be another
explanation for the lower T3 levels in non-survivors
compared with survivors during follow-up.
The question whether critical ill patients with low
thyroid hormones should be treated with thyroid hormone
replacement is controversially disputed [27, 37–40]. In a
small study, infusion of T4 to critically ill patients
restored T4 levels but failed to show a clinical benefit
[38]. In a study of severely burned patients given 200 lg
T3 daily, there was again no evidence of a beneficial or a
disadvantageous effect [39]. However, improved myo-
cardial function and the need for a reduced amount of
vasopressor have been observed with T3 infusion in adults
upon coronary artery bypass surgery [37, 40]. Pioneering
studies by van den Berghe in patients with severe
euthyroid sick syndrome showed that co-administration of
TRH, growth hormone-releasing hormone, and growth
hormone-releasing peptide 2 reduces protein catabolism
by restoring physiologic hormone levels [27, 41]. The
lack of an association of low T3/fT4 levels with the
outcome in this study questions the potential usefulness of
thyroid hormone treatment in critically ill patients as
advocated by some authors [38, 39]. Only prospective
intervention studies can give conclusive answers to this
question.
Some limitations of this study merit consideration. First,
this study is observational in nature. Second, the number of
events (deaths) in this analysis is of only moderate size
limiting the statistical power. Third, we analyzed patients
with a diversity of conditions, but therewith reflecting the
real-life situation on a medical ICU, which is dominated by
heterogeneity. Fourth, we did not measure TSH levels
which, most likely, would not have changed the main
conclusion of our study.
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Conclusion
In conclusion, T3 and fT4 levels on admission were not
prognostic in septic and non-septic critically ill patients. A
decrease of fT4 levels during the follow-up may point to
adverse outcome, whereas increasing peripheral thyroid
hormones may be an indicator for a good prognostic
course.
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